Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention

American Heart Journal

Volumn 138, Issue 1 I, 1999, Pages 49-54

  Dangas, G ^a   Marmur, J D ^a   King, T E ^a   De Leon, J ^a   Sharma, S K ^a   Vidhun, R ^a   Feldman, D ^a   Stoynov, M Y ^a   Badimon, J J ^a   Ambrose, J A ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; THROMBIN;

ADULT; ARTICLE; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MALE; PRIORITY JOURNAL; THROMBOGENESIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0032779406     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70245-0     Document Type: Article

References (28)

1. Fernandez-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994;23:1562-9.
2. Marmur JD, Thiruvikraman SV, Fyfe BS, Guha A, Sharma SK, Ambrose JA, et al. Identification of active tissue factor in human coronary atheroma. Circulation 1996;94:1226-32.
3. Kirchhofer D, Tschopp B, Steiner B, Baumgartner HR. Role of collagen-adherent platelets in mediating fibrin formation in flowing whole blood. Blood 1995;86:3815-22.
4. Kumar R, Beguin S, Hemker HC. The influence of fibrinogen and fibrin on thrombin generation. Evidence for feedback activation of the clotting system by clot bound thrombin. Thromb Haemost 1994;72:713-21.
5. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997;95:594-9.
6. Dangas G, Fuster V. Management of restenosis after coronary intervention. Am Heart J 1996;132:428-36.
7. Coller BS, Anderson K, Weisman HF. New antiplatelet agents: platelet GP IIb/IIIa antagonists. Thromb Haemost 1995;74:301-8.
8. EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in a high risk coronary angioplasty. N Engl J Med 1994;330:956-61.
9. The EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
10. The CAPTURE investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35.
11. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
12. The IMPACT II Investigators. Randomized placebo-controlled trial of effect of eptifibatide on complication of percutaneous coronary intervention: IMPACT II. Lancet 1997;349:1422-8.
13. Coller BS. A new murine monoclonal antibody reports and activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985;76:101-8.
14. Konstantopoulos K, Kamat SG, Schafer AI, Banez EI, Jordon R, Kleiman NS, et al. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, abciximab, in patients undergoing coronary angioplasty. Circulation 1995;91:1427-31.
15. Turner NA, Moake JL, Kamat SG, Schafer AI, Kleiman NS, Jordan R, et al. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb/IIIa. Circulation 1995;91:1354-62.
16. Reverter JC, Beguin S, Kessels H, Kumar R, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effects of abciximab treatment on acute thrombosis and "clinical restenosis." J Clin Invest 1996;98:863-74.
17. Dangas G, Badimon JJ, Coller BS, Fallon JT, Sharma SK, Hayes RM, et al. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab. Arterioscl Thromb Vasc Biol 1998; 18:1342-9.
18. Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway using radio-immunoassays for the F2/F1+2 fragment and thrombin-anitithrombin complex. Blood 1982;59:1086-97.
19. Nossel HL, Ti M, Kaplan KL, Spanondis K, Soland T, Butler VP Jr. The generation of fibrinopeptide A in clinical blood samples. Evidence for thrombin activity. J Clin Invest 1976;58:1136-44.
20. Braunwald E. Unstable angina: a classification. Circulation 1989; 80:410-4.
21. Dangas G, Mehran R, Wallenstein S, Courcoutsakis NA, Kakarala V, Hollywood J, et al. Correlation between angiographic morphology and clinical presentation in unstable angina. J Am Coll Cardiol 1997;29:519-25.
22. Ryan TJ, Faxon DP, Gunnar RM. Guidelines for percutaneous transluminal coronary angioplasty: A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 1988;12:529-45.
23. Cadroy Y, Hanson SR, Andrew BK, Marzec UM, Evatt BL, Kunicki TJ, et al. Relative antithrombotic effects of monoclonal antibodies treating different platelet glycoprotein-adhesive molecule interactions in nonhuman primates. Blood 1994;83:3218-25.
24. Weiss HJ, Turitto VT, Baumgartner HR. Role of shear rate and platelets in promoting fibrin formation on rabbit subendothelium. Studies utilizing patients with quantitative and qualitative platelet defects. J Clin Invest 1986;78:1072-82.
25. Marmur JD, Merlini PA, Sharma SK, Khaghan N, Torre SR, Israel DH, et al. Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty. J Am Coll Cardiol 1994;24:1484-91.
26. Marmur JD, Sharma SK, Weinrauch M, Kantrowitz N, Dangas G, Kokkinakis S, et al. Thrombin generation and activity during coronary angioplasty: influence of angiographic lesion morphology. J Invas Cardiol 1997;9:410-6.
27. Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, et al for the EPIC study investigators. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy. Am J Cardiol 1995;75:559-62.
28. Ammar T, Scudder LE, Coller BS. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist abciximab on the activated clotting time. Circulation 1997;95:614-7.